Cambridge University intends to hold clinical trials of anti-Covid-19 vaccine in autumn

Source : 112 Ukraine

The British government provided the university with 1.9 million pounds sterling financing
16:50, 26 August 2020


Cambridge University intends to start clinical trials of its vaccine against coronavirus in autumn as the British government provided 1.9 million pounds sterling financing, as the university reported.

“A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK in late autumn or early next year, thanks to a £1.9million award from the UK government,” the message said.

The scientists who developed the vaccine stated that their approach that uses genetic sequences of all known coronaviruses for sharpening of the immune response might help to avoid side effects from the hyper-inflammatory immune responses.

Related: First batch of coronavirus vaccine produced in Russia

Thus, the Cambridge vaccine, DIOS-CoVax2, is based on DNA. The structures of the antigens are coded by synthetic genes that might reprogram the immune system to produce antibodies against the coronavirus.

Moreover, the university showed that this method of DNA-vector is safe and effective for stimulating an immune response against other pathogens in multiple phases. Besides, it can be used without needles and it may simplify the widespread of the vaccine.

On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.

It is noted that the vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and Russian Binnopharm Company. According to Murashko, finalizing takes place of the technical regulations for scaling of production at the number of Russian productions.

Related: Health Ministry to buy 1.5 mln vaccines from flu for doctors, teachers, police and Border Guards

However, the WHO doubted the safety of the Russian vaccine against Covid-19.

Later, China reported registering its first vaccine against coronavirus. It is stated that the application for the patent was filed in March but it was approved only now. The patent is issued by the National Intellectual Property Administration.

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more